Julia Kaplun, MD
Endocrinology · Suffern, NYNPI 1306809181
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,157, 2.7 times the $425 reported in 2019.
Across 286 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$600
- Lilly USA, LLC$530
- Tandem Diabetes Care, Inc.$500
- Corcept Therapeutics$294
- Mannkind Corporation$289
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$5008%
- Food & beverage$5,37991%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $1,193 |
| Amgen(2 entities) | 16 | $600 |
| Lilly USA, LLC | 31 | $530 |
| Tandem Diabetes Care, Inc. | 2 | $500 |
| Corcept Therapeutics | 12 | $294 |
| Mannkind Corporation | 26 | $289 |
| Sanofi-aventis U.S. LLC | 9 | $264 |
| AbbVie | 14 | $241 |
| Dexcom, Inc. | 7 | $229 |
| Abbott | 11 | $226 |
| Bayer | 8 | $159 |
| AstraZeneca | 8 | $139 |
| Boehringer Ingelheim | 6 | $123 |
| Xeris Pharmaceuticals, Inc. | 5 | $114 |
| Insulet Corporation | 6 | $102 |
| Pfizer | 5 | $100 |
| Embecta Corp. | 4 | $92 |
| Antares Pharma, Inc. | 4 | $82 |
| Radius Health, Inc. | 4 | $79 |
| IBSA Pharma Inc. | 4 | $76 |
| GSK | 3 | $75 |
| Amneal Pharmaceuticals LLC | 3 | $54 |
| Madrigal Pharmaceuticals | 1 | $48 |
| BD | 2 | $39 |
| Chiesi USA, Inc. | 2 | $36 |
| Medtronic | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Sandoz | 1 | $27 |
| Merck | 2 | $27 |
| RGH Enterprises LLC | 1 | $17 |
| Halozyme Inc | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Valeritas, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$500
- EVENITY$270
How this compares
$5,891 in reported general payments places this provider in the 85th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $359,718 |
| MounjaroTirzepatide | 95 | $162,826 |
| JardianceEmpagliflozin | 120 | $160,298 |
| TrulicityDulaglutide | 49 | $79,858 |
| JanuviaSitagliptin Phosphate | 55 | $66,854 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $51,469 |
| FarxigaDapagliflozin Propanediol | 21 | $30,563 |
| TradjentaLinagliptin | 23 | $25,482 |
| ProliaDenosumab | 14 | $25,059 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $22,362 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $20,228 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $18,021 |
| Cinacalcet Hcl | 25 | $16,933 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $16,333 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $15,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,193 | $359,718202 claims |
| Lilly USA, LLCMounjaro, Trulicity | $530 | $242,684144 claims |
| Boehringer IngelheimJardiance, Tradjenta | $123 | $185,779143 claims |
| MerckJanuvia, Janumet, Janumet Xr | $27 | $133,654117 claims |
| AstraZenecaFarxiga | $139 | $30,56321 claims |
| AmgenProlia | $600 | $25,05914 claims |
| AbbVieSynthroid | $241 | $12,819186 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $54 | $5,579420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 endocrinology providers in New York.
Other endocrinology in Suffern
- Philip RabitoNew York$712K
- Perry HersonWilliston Park$364K
- Olga LeonardiNew York$10K
- Isabela RomaoNew Hyde Park$10K
- Stephanie CharlesWest Nyack$10K
- Sanjay SahayGarden City$9K
- Norma QuijadaOrchard Park$8K
- Swaminathan GiridharanBrooklyn$7K
- Elia KassabBrooklyn$1K
- Lauren GoldenNew York$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.